In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success. EXCLUSIVE OFFER: Get the inside scoop on opportunities in PETX with the Ticky from Trade-Ideas. See the FREE profile for PETX NOW at Trade-Ideas More details on PETX: Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, development, and commercialization of biopharmaceutical products for the companion animals worldwide. Currently there are 8 analysts that rate Aratana Therapeutics a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Aratana Therapeutics has been 407,900 shares per day over the past 30 days. Aratana has a market cap of $593.4 million and is part of the health care sector and drugs industry. The stock has a beta of 3.67 and a short float of 11.4% with 8.92 days to cover.